An ECRI Institute Web Conference
Transcatheter aortic valve implantation (TAVI) is a percutaneous procedure intended to provide a new treatment option for patients with severe aortic stenosis who are not candidates for open valve replacement surgery and do not qualify for other treatment options.
Severe aortic stenosis is a life-threatening, progressive disease that affects approximately 360,000 individuals—predominantly age 65 or older—in the U.S. Currently, the FDA-approved indications for the procedure include inoperable severe aortic stenosis and patients who are operable but at high risk for complications or death.
In "Considerations for Implementing a Transcatheter Aortic Valve Implantation Service," presenters from ECRI Institute discuss the wide-ranging issues the procedure presents to hospitals, and preview findings from their technology assessment of TAVI.
- Provides safety and efficacy information to help inform patient selection
- Helps health plan executives determine coverage policies
- Addresses the complex infrastructure and staffing requirements for TAVI
- Discusses the financial considerations and implications for creating a TAVI program
- Hospital administrators
- Value analysis and technology assessment committee members, including physicians and nurses
- Health plan medical policy staff, including nurses and medical directors
- Cardiac clinical service personnel